Ministry of Public Health promises to treat COVID-19 A panel of medical experts is to be considered based on academic knowledge.
Today (13 September 2022) at the Ministry of Public Health (PTI) Dr Rungruang Kitphati, MD. Chief Advisor at Ministry Level (Qualified Level 11 Dr) and spokesman for the Ministry of Health revealed the cause of many medical scholars expressing concern about the effectiveness of favipiravir, saying that various measures related to COVID-19 in Thailand, including disease control medical treatment The MoPH operates as a committee made up of academics and specialist doctors from leading medical institutions. Take into account the knowledge of academic education in the country and abroad. Favipiravir was the first drug to be used since the outbreak began. which at the time was a strain that caused severe symptoms of a lung infection
“According to the results of the study of the Faculty of Medicine Siriraj Hospital Mahidol University in collaboration with the Bamrasnadura Institute, Department of Disease Control and Division of Genomic Medicine and supporting the innovation of the Department of Medical Sciences in patients with COVID-19 with mild or moderate symptoms no pneumonia and received medication from the first day of symptoms A follow-up assessment at the hospital by medical personnel found that the symptoms of the Covid-19 patients clearly improved more quickly than those who did not receive the drug. (Half improvement in 2 days when given compared to 14 days in the no drug group),” said Dr. Ruang Ruang.
A spokesman for the Ministry of Public Health said overseas research on favipiravir was being carried out at various times. There are also differences in details about Thai education and practical use. which since using this drug The rate of loss decreases accordingly. Currently, the death rate from COVID-19 in Thailand is less than 0.1 percent, or less than 1 case in 1,000 cases, which is currently very low among people under 18 .
“The expert committee has been tracking information about treatments. related new research results continuously to adjust the treatment guidelines accordingly. Other drugs that are supported by studies are also used, such as remdisivir, which is an injectable drug. It has the same mechanism of action as Favipiravir. For patients with drug absorption problems unable to eat including pregnant women Molnupiravir (Molnupiravir) is an oral medication for adults. have the same mechanism of action Reduce the risk of severe symptoms Must be given within 5 days of the onset of symptoms. and Paxlovid has a mechanism of action that is an enzyme that reduces the number of germs that is distributed to different hospitals After being approved by the Operations Center, the Ministry of Public Health and the Center for the Administration of the Covid-19 Situation (CDC), the information on the effectiveness of favipiravir is currently published. Academic Committee It has been recognized and will be taken into account for further improvement of the appropriate treatment guidelines,” said Dr. Ruangrueng.
